Lisa Sanderson Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa Sanderson Cox has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Matthew S. Mayo
Department of Biostatistics and Data Science, The University of Kansas Medical Center, Kansas City, KS, USA
7 shared publications - Nicole Nollen
Department of Population Health, University of Kansas Medical Center
7 shared publications - Edward F. Ellerbeck
Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
5 shared publications Jasjit S. Ahluwalia
Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island
5 shared publicationsMatthew S. Mayo
University of Kansas Cancer Center, Kansas City
4 shared publications- Babalola Faseru
Department of Population Health, University of Kansas School of Medicine, Kansas City, KS, USA
3 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by Elsevier in Addictive Behaviors
- Vol. 170, 108431
Characteristics associated with medication adherence in a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in black adults who smoke
- 15 July 2025
- Published by Elsevier in Addictive Behaviors
- Vol. 170, 108431
Open AccessCharacteristics associated with medication adherence in a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in black adults who smoke
- Open Access
- 5 November 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 30, 101032
Protocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke
- 5 November 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 30, 101032
Open AccessProtocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke
- Open Access
- 14 June 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (22) , 2201-2209
Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers
Black adults in the US have higher rates of smoking-related morbidity and mortality compared with White adults, despite having comparable smoking prevalence and smoking fewer cigarettes per day.1-4 Although they report greater interest in quitting, Black smokers are less likely than White smokers to be advised to quit or achieve sustained smoking abstinence and have been underrepresented in tobacco treatment research.1,5 Advancing treatment for Black smokers must include light smokers, because more than 65% of Black individuals who smoke use 10 or fewer cigarettes per day.2,6 Light smokers report nicotine dependence and experience substantial tobacco-related disease,7-10 but have been largely excluded from smoking cessation clinical trials.11,12 Clinical practice guidelines articulate the need for research addressing treatment for light smokers and for Black smokers.12,13
- 14 June 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (22) , 2201-2209
Open AccessEffect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers
Black adults in the US have higher rates of smoking-related morbidity and mortality compared with White adults, despite having comparable smoking prevalence and smoking fewer cigarettes per day.1-4 Although they report greater interest in quitting, Black smokers are less likely than White smokers to be advised to quit or achieve sustained smoking abstinence and have been underrepresented in tobacco treatment research.1,5 Advancing treatment for Black smokers must include light smokers, because more than 65% of Black individuals who smoke use 10 or fewer cigarettes per day.2,6 Light smokers report nicotine dependence and experience substantial tobacco-related disease,7-10 but have been largely excluded from smoking cessation clinical trials.11,12 Clinical practice guidelines articulate the need for research addressing treatment for light smokers and for Black smokers.12,13
- Open Access
- 15 October 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (20) , 10859
Feasibility and Effectiveness of Recruiting Latinos in Decídetexto—A Smoking Cessation Clinical Trial from an Emergency Department Patient Registry
There is an underrepresentation of Latinos in smoking cessation clinical trials. This study describes the feasibility and effectiveness of recruiting Latino smokers in the U.S. from an emergency department (ED) patient registry into a randomized smoking cessation clinical trial. Recruitment occurred from the Hackensack University Medical Center ED. Potential participants were contacted from a patient registry. The primary outcome was whether the participant responded to a call or text. Secondary outcomes included the best day of the week, week of the month, and time of day to obtain a response. Of the 1680 potential participants, 1132 were called (67.5%), while 548 (32.5%) were texted. For calls, response rate was higher compared to text (26.4% vs 6.4%; p < 0.001). More participants were interested in the study when contacted by calls compared to text (11.4% vs. 1.8%) and more participants were enrolled in the study when contacted by calls compared to text (1.1% vs. 0.2%). Regression models showed that ethnicity, age, time of day, and week of the month were not significantly associated with response rates. Recruitment of Latinos from an ED patient registry into a smoking cessation clinical trial is feasible using call and text, although enrollment may be low.
- 15 October 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (20) , 10859
Open AccessFeasibility and Effectiveness of Recruiting Latinos in Decídetexto—A Smoking Cessation Clinical Trial from an Emergency Department Patient Registry
There is an underrepresentation of Latinos in smoking cessation clinical trials. This study describes the feasibility and effectiveness of recruiting Latino smokers in the U.S. from an emergency department (ED) patient registry into a randomized smoking cessation clinical trial. Recruitment occurred from the Hackensack University Medical Center ED. Potential participants were contacted from a patient registry. The primary outcome was whether the participant responded to a call or text. Secondary outcomes included the best day of the week, week of the month, and time of day to obtain a response. Of the 1680 potential participants, 1132 were called (67.5%), while 548 (32.5%) were texted. For calls, response rate was higher compared to text (26.4% vs 6.4%; p < 0.001). More participants were interested in the study when contacted by calls compared to text (11.4% vs. 1.8%) and more participants were enrolled in the study when contacted by calls compared to text (1.1% vs. 0.2%). Regression models showed that ethnicity, age, time of day, and week of the month were not significantly associated with response rates. Recruitment of Latinos from an ED patient registry into a smoking cessation clinical trial is feasible using call and text, although enrollment may be low.
- 16 October 2017
- Published by Taylor & Francis in Ethnicity & Health
- Vol. 24 (8) , 855-873
Intent to quit, quit attempts, and perceived health risk reduction among African American, Latino, and White nondaily and daily smokers in the United States
Objective: Ethnic and racial differences in smoking patterns and behaviors have been well documented and most African American and Latino smokers are nondaily or light smokers. However, differences within smoking levels are understudied. Our primary aim was to determine whether there are racial and ethnic differences among African American, Latino, and White nondaily, light daily, and moderate to heavy daily smokers on (1) perceived health risk reduction, (2) intentions to quit, and (3) past year quit attempts. Design: Smokers were recruited through an online research panel for a cross-sectional survey (n = 2376). Sampling quotas were used to obtain equal numbers of African American, Latino, and White nondaily and daily smokers. Results: African American (59.6%) and Latino (54%) nondaily smokers were more likely than White nondaily smokers (45%) to currently limit their cigarettes per day (cpd) as a perceived health risk reduction strategy (p < 0.05). African American nondaily smokers were more likely than Latino and White nondaily smokers (p < 0.05) to limit their smoking in the past year as a perceived health risk reduction strategy (range: 0 ‘never’ to 5 ‘always’; Means = 3.2, 2.9, 3.0, standard deviations [SD] = 1.1, 1.1, 1.2, respectively). African American nondaily smokers (15%) were more likely than either Latinos (7.8%) or Whites (8.5%) to intend to quit in the next 30 days (p < 0.01). African American (61.6%) and Latino (60.3%) nondaily smokers were more likely than Whites (49%) to have made a quit attempt in the past year (p < 0.01). Fewer racial and ethnic differences were found among daily smokers. Conclusions: Racial and ethnic group differences were more pronounced among nondaily smokers compared to light daily smoker and moderate to heavy daily smokers. Smoking level is an important consideration in understanding racial and ethnic variation in perceived health risk reduction and cessation-related behaviors.
- 16 October 2017
- Published by Taylor & Francis in Ethnicity & Health
- Vol. 24 (8) , 855-873
Intent to quit, quit attempts, and perceived health risk reduction among African American, Latino, and White nondaily and daily smokers in the United States
Objective: Ethnic and racial differences in smoking patterns and behaviors have been well documented and most African American and Latino smokers are nondaily or light smokers. However, differences within smoking levels are understudied. Our primary aim was to determine whether there are racial and ethnic differences among African American, Latino, and White nondaily, light daily, and moderate to heavy daily smokers on (1) perceived health risk reduction, (2) intentions to quit, and (3) past year quit attempts. Design: Smokers were recruited through an online research panel for a cross-sectional survey (n = 2376). Sampling quotas were used to obtain equal numbers of African American, Latino, and White nondaily and daily smokers. Results: African American (59.6%) and Latino (54%) nondaily smokers were more likely than White nondaily smokers (45%) to currently limit their cigarettes per day (cpd) as a perceived health risk reduction strategy (p < 0.05). African American nondaily smokers were more likely than Latino and White nondaily smokers (p < 0.05) to limit their smoking in the past year as a perceived health risk reduction strategy (range: 0 ‘never’ to 5 ‘always’; Means = 3.2, 2.9, 3.0, standard deviations [SD] = 1.1, 1.1, 1.2, respectively). African American nondaily smokers (15%) were more likely than either Latinos (7.8%) or Whites (8.5%) to intend to quit in the next 30 days (p < 0.01). African American (61.6%) and Latino (60.3%) nondaily smokers were more likely than Whites (49%) to have made a quit attempt in the past year (p < 0.01). Fewer racial and ethnic differences were found among daily smokers. Conclusions: Racial and ethnic group differences were more pronounced among nondaily smokers compared to light daily smoker and moderate to heavy daily smokers. Smoking level is an important consideration in understanding racial and ethnic variation in perceived health risk reduction and cessation-related behaviors.
- 1 October 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 179, 330-336
Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products
- 1 October 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 179, 330-336
Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products
- Open Access
- 1 March 2016
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 47, 12-21
A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics
- 1 March 2016
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 47, 12-21
Open AccessA clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics
- 1 July 2014
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 38 (2) , 173-181
Design and participant characteristics of a randomized-controlled trial of telemedicine for smoking cessation among rural smokers
- 1 July 2014
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 38 (2) , 173-181
Design and participant characteristics of a randomized-controlled trial of telemedicine for smoking cessation among rural smokers
- Open Access
- 25 January 2012
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 104 (4) , 290-298
Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial
Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers. We evaluated whether bupropion SR was effective for smoking cessation among African American light smokers (≤10 CPD). A randomized, double-blind placebo-controlled trial was conducted from December 27, 2007, to May 13, 2010. All participants were African American light smokers (≤10 CPD), aged 18 years or older. Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once daily for 3 days and then 150 mg twice daily) (n = 270 participants) or placebo (n = 270 participants) for 7 weeks, and up to six sessions of health education counseling. Serum cotinine was measured at baseline (week 0). The primary outcome was salivary cotinine–verified 7-day point prevalence smoking abstinence at week 26; a cut point of 15 ng/mL differentiated smokers from nonsmokers. Salivary cotinine–verified smoking abstinence at end of medication treatment at week 7 was also examined. Odds ratios (OR) for smoking abstinence and 95% confidence intervals (CIs) were calculated using logistic regression models. All statistical tests were two-sided. Participants at baseline visit (week 0) smoked an average of 8.0 CPD and had a mean serum cotinine level of 275.8 ng/mL (SD = 155.8 ng/mL); most used menthol cigarettes (83.7%) and smoked within 30 minutes of waking (72.2%). After imputing those lost to follow-up as smokers, no statistically significant difference in long-term smoking abstinence rates at week 26 was observed between bupropion SR and placebo groups (13.3% vs 10.0%, OR = 1.39, 95% CI = 0.82 to 2.35, P = .23). Cotinine-verified smoking abstinence rate at end of medication week 7 was higher in the bupropion SR vs placebo group (23.7% vs 9.6%, OR = 2.92, 95% CI = 1.78 to 4.77, P < .001). Bupropion SR was effective in promoting smoking cessation during the medication phase of treatment but showed no effect on long-term smoking cessation among African American light smokers. More research is needed to identify strategies for sustaining abstinence among African American light smokers.
- 25 January 2012
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 104 (4) , 290-298
Open AccessBupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial
Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers. We evaluated whether bupropion SR was effective for smoking cessation among African American light smokers (≤10 CPD). A randomized, double-blind placebo-controlled trial was conducted from December 27, 2007, to May 13, 2010. All participants were African American light smokers (≤10 CPD), aged 18 years or older. Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once daily for 3 days and then 150 mg twice daily) (n = 270 participants) or placebo (n = 270 participants) for 7 weeks, and up to six sessions of health education counseling. Serum cotinine was measured at baseline (week 0). The primary outcome was salivary cotinine–verified 7-day point prevalence smoking abstinence at week 26; a cut point of 15 ng/mL differentiated smokers from nonsmokers. Salivary cotinine–verified smoking abstinence at end of medication treatment at week 7 was also examined. Odds ratios (OR) for smoking abstinence and 95% confidence intervals (CIs) were calculated using logistic regression models. All statistical tests were two-sided. Participants at baseline visit (week 0) smoked an average of 8.0 CPD and had a mean serum cotinine level of 275.8 ng/mL (SD = 155.8 ng/mL); most used menthol cigarettes (83.7%) and smoked within 30 minutes of waking (72.2%). After imputing those lost to follow-up as smokers, no statistically significant difference in long-term smoking abstinence rates at week 26 was observed between bupropion SR and placebo groups (13.3% vs 10.0%, OR = 1.39, 95% CI = 0.82 to 2.35, P = .23). Cotinine-verified smoking abstinence rate at end of medication week 7 was higher in the bupropion SR vs placebo group (23.7% vs 9.6%, OR = 2.92, 95% CI = 1.78 to 4.77, P < .001). Bupropion SR was effective in promoting smoking cessation during the medication phase of treatment but showed no effect on long-term smoking cessation among African American light smokers. More research is needed to identify strategies for sustaining abstinence among African American light smokers.